Suppliers / Rafarm

Rafarm

Greece 460 employees 2 duplicate records merged Updated 9 July 2026

Rafarm is a contract manufacturer based in Greece. It appears in 54 regulatory filings across 9 regulators, without an active US DMF or CEP on file. Its filings concentrate with INFARMED (PT), MINSA (CR) and EFDA (ET). Its GMP standing is certified by EMA, NAFDAC (NG) and US FDA. Its most recent recorded inspection, by US FDA, closed on 21 June 2024 as VAI. Customs aggregates show $130 of exports covering 2 molecules to 1 destination in 2022.

0
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
54
filings across 9 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 21 June 2024 VAI US FDA
  • 19 May 2023 NAI US FDA
  • 4 June 2021 VAI US FDA
  • 11 March 2020 NAI US FDA
  • 31 May 2018 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Paiania, United Arab Emirates Not on file
Paiania Attiki, United Arab Emirates Not on file
LONDON, United Kingdom Not on file
Paiania, Greece Not on file
Greece, Greece 3009592290

Filings and GMP by regulator

Regulator Filings GMP certificates
INFARMED (PT) 36 None
MINSA (CR) 5 None
EFDA (ET) 3 None
DPM (TN) 3 None
ANPP (DZ) 2 None
ARCSA (EC) 2 None
EMA None 1
NAFDAC (NG) None 1
US FDA None 1

Scale

Year Revenue Exports Destinations
2022 Not reported $130 1

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Rafarm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 June 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts